HOOKIPA Pharma (HOOK) Competitors

Century Therapeutics (NASDAQ:IPSC) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Is IPSC or HOOK more profitable?

Century Therapeutics has a net margin of -19.10% compared to HOOKIPA Pharma's net margin of -785.66%. Century Therapeutics' return on equity of -11.53% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-19.10%	-11.53%	-6.94%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

Do insiders and institutionals believe in IPSC or HOOK?

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 5.0% of Century Therapeutics shares are held by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings & valuation, IPSC or HOOK?

HOOKIPA Pharma has lower revenue, but higher earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$114.13M	0.44	-$126.57M	-$0.29	-2.01
HOOKIPA Pharma	$9.35M	1.20	-$43.50M	-$4.73	-0.19

Does the media prefer IPSC or HOOK?

In the previous week, Century Therapeutics had 4 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 4 mentions for Century Therapeutics and 0 mentions for HOOKIPA Pharma. Century Therapeutics' average media sentiment score of 0.00 equaled HOOKIPA Pharma'saverage media sentiment score.

Company	Overall Sentiment
Century Therapeutics	Neutral
HOOKIPA Pharma	Neutral

Do analysts prefer IPSC or HOOK?

Century Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 542.67%. HOOKIPA Pharma has a consensus price target of $4.50, suggesting a potential upside of 389.13%. Given Century Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Century Therapeutics is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
HOOKIPA Pharma	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Which has more risk and volatility, IPSC or HOOK?

Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Summary

Century Therapeutics beats HOOKIPA Pharma on 11 of the 15 factors compared between the two stocks.